Ambroxol HClTTX-resistant Na+ currents inhibitor CAS# 23828-92-4 |
- AM-095 free base
Catalog No.:BCC1352
CAS No.:1228690-36-5
- AM095
Catalog No.:BCC1351
CAS No.:1345614-59-6
- Ki16198
Catalog No.:BCC4560
CAS No.:355025-13-7
- Ki16425
Catalog No.:BCC1155
CAS No.:355025-24-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 23828-92-4 | SDF | Download SDF |
PubChem ID | 108013 | Appearance | Powder |
Formula | C13H19Br2ClN2O | M.Wt | 414.56 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 50 mM in DMSO | ||
Chemical Name | 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydrochloride | ||
SMILES | C1CC(CCC1NCC2=CC(=CC(=C2N)Br)Br)O.Cl | ||
Standard InChIKey | QNVKOSLOVOTXKF-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C13H18Br2N2O.ClH/c14-9-5-8(13(16)12(15)6-9)7-17-10-1-3-11(18)4-2-10;/h5-6,10-11,17-18H,1-4,7,16H2;1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Sodium channel blocker and mucolytic agent with antioxidant, anti-viral and anti-inflammatory properties. Inhibits tetrodotoxin (TTX)-resistant channels more potently than TTX-sensitive subtypes (IC50 values for tonic block are 35.2 and 111.5 μM respectively). Inhibits release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. |
Ambroxol HCl Dilution Calculator
Ambroxol HCl Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.4122 mL | 12.061 mL | 24.122 mL | 48.2439 mL | 60.3049 mL |
5 mM | 0.4824 mL | 2.4122 mL | 4.8244 mL | 9.6488 mL | 12.061 mL |
10 mM | 0.2412 mL | 1.2061 mL | 2.4122 mL | 4.8244 mL | 6.0305 mL |
50 mM | 0.0482 mL | 0.2412 mL | 0.4824 mL | 0.9649 mL | 1.2061 mL |
100 mM | 0.0241 mL | 0.1206 mL | 0.2412 mL | 0.4824 mL | 0.603 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
AmbroxolHCl is a potent inhibitor of the neuronal Na+ channels, inhibits TTX-resistant Na+ currents with IC50 of 35.2 μM and 22.5 μM for tonic and phasic block, inhibits TTX-sensitive Na+ currents with IC50 of 100 μM. Phase 3.
- Ac-Trp-OEt
Catalog No.:BCC3110
CAS No.:2382-80-1
- Trichokaurin
Catalog No.:BCN4851
CAS No.:23811-50-9
- Hinesol
Catalog No.:BCC9232
CAS No.:23811-08-7
- Pogostone
Catalog No.:BCN2696
CAS No.:23800-56-8
- 6-Hydroxyindole
Catalog No.:BCN8310
CAS No.:2380-86-1
- Homovanillyl alcohol
Catalog No.:BCN7173
CAS No.:2380-78-1
- 4-Aminopyrazolo[3,4-d]pyrimidine
Catalog No.:BCC8690
CAS No.:2380-63-4
- Methylprednisolone Sodium Succinate
Catalog No.:BCC5629
CAS No.:2375-03-3
- Rivulobirin E
Catalog No.:BCN5090
CAS No.:237407-59-9
- 4-Amino-3-hydroxybenzoic acid
Catalog No.:BCC8681
CAS No.:2374-03-0
- trans-3'-O-Benzoyl-4'-O-methylkhellactone
Catalog No.:BCN6921
CAS No.:23733-95-1
- trans-Methylkhellactone
Catalog No.:BCN6919
CAS No.:23733-92-8
- Liensinine perchlorate
Catalog No.:BCN6335
CAS No.:2385-63-9
- Ethyl2-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylate
Catalog No.:BCC8979
CAS No.:238749-50-3
- Tosedostat (CHR2797)
Catalog No.:BCC2309
CAS No.:238750-77-1
- Zapotinin
Catalog No.:BCC9192
CAS No.:14813-20-8
- Boc-Lys(Z)-OH
Catalog No.:BCC2722
CAS No.:2389-45-9
- H-Lys(Boc)-OMe.HCl
Catalog No.:BCC2983
CAS No.:2389-48-2
- Z-Lys(Boc)-OH
Catalog No.:BCC2763
CAS No.:2389-60-8
- Dexamethasone dipropionate
Catalog No.:BCC8934
CAS No.:55541-30-5
- Alphaxalone
Catalog No.:BCC7545
CAS No.:23930-19-0
- 5-(2-Aminopropyl)-7-cyanoindolin-1-yl)propyl benzoate
Catalog No.:BCC8718
CAS No.:239463-72-0
- 5-[(2R)-2-Aminopropyl]-1-[3-(benzoyloxy)propyl]-2,3-dihydro-1H-indole-7-carbonitrile (2R,3R)-2,3-dihydroxybutanedioate
Catalog No.:BCN1479
CAS No.:239463-85-5
- Glochidonol
Catalog No.:BCN5091
CAS No.:23963-54-4
[Effects of ambroxol HCl on the guinea pig tracheal mucous secretion and the rat pulmonary surfactant secretion].[Pubmed:1446879]
Nihon Yakurigaku Zasshi. 1992 Oct;100(4):293-300.
The effects of orally administered Ambroxol HCl (ambroxol) on guinea pig tracheal mucous secretion and rat pulmonary surfactant secretion were investigated histologically and biochemically. Ambroxol significantly increased the number of active goblet cells in guinea pig tracheal epithelium and total mucopolysaccharide level. Moreover, ambroxol significantly increased the neutral mucopolysaccharide level and PAS-positive substance in the guinea pig tracheal submucosal glands. Ambroxol did not show a significant effect on the content of the total phosphatidylcholine in rat lung lavage fluid, while ambroxol significantly increased the ratio of disaturated phosphatidylcholine to total phosphatidylcholine. From these results, it is suggested that ambroxol increases both the tracheal mucous secretion, especially the neutral mucopolysaccharide, and pulmonary surfactant secretion and these effects reflect part of the expectorant mechanism of the drug.
Inhibition of tetrodotoxin (TTX)-resistant and TTX-sensitive neuronal Na(+) channels by the secretolytic ambroxol.[Pubmed:12181417]
Mol Pharmacol. 2002 Sep;62(3):433-8.
Ambroxol has a long history for the treatment of airway diseases because of its beneficial effects on surfactant synthesis and mucus-modifying properties. Some findings, however, point to an additional effect on neuronal signal transduction: ambroxol can suppress reflexes such as the cough or the corneal reflex. The airways and the cornea are innervated by C-fibers, which express voltage-gated Na(+) channels with and without sensitivity to tetrodotoxin (TTX). In this study, we performed voltage-clamp experiments to investigate whether ambroxol affects these channel types. In rat dorsal root ganglia, TTX-resistant Na(+) currents were suppressed in a concentration-dependent manner with IC(50) values of 35.2 and 22.5 microM for tonic and phasic block, respectively. Depolarizing prepulses increased the potency of ambroxol, and steady-state inhibition curves were shifted to more negative values. The inhibition was not frequency-dependent. TTX-sensitive currents were inhibited with lower potency (approximately 50% inhibition with 100 microM). Recombinant rat brain IIA channels in Chinese hamster ovary cells were blocked with IC(50) values of 111.5 and 57.6 microM for tonic and phasic block, respectively; in contrast to TTX-resistant channels the block was frequency-dependent. Thus, ambroxol indeed blocks neuronal voltage-gated Na(+) channels, and TTX-resistant channels in sensory neurons were more sensitive than TTX-sensitive. Compared with known local anesthetics (e.g., lidocaine or benzocaine), the potency for Na(+) channel block was relatively high. A recent clinical trial has further confirmed that ambroxol relieved pain and was beneficial in patients who suffered from sore throat.
Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells.[Pubmed:10202994]
Inflamm Res. 1999 Feb;48(2):86-93.
OBJECTIVES AND DESIGN: The effects of the mucolytic agents ambroxol and N-acetylcystein (NAC) were studied on the release of histamine, leukotrienes, cytokines and superoxide anions from a variety of cells involved in the pathogenesis of allergic inflammation. SUBJECTS: Mast cells were isolated from human adenoids and skin (n = 5-6). Basophils, monocytes and granulocytes were obtained from Buffy-coat blood obtained from healthy blood donors (n = 4-7) and enriched by density centrifugation. TREATMENT AND METHODS: Ambroxol or NAC were added to the cells for different periods before stimulation with various immunological and non-immunological secretagogues. Histamine release from mast cells, basophils and monocytes was assayed either by radioimmunoassay or spectrofluorometrically. LTC4 (basophils), LTB4 (neutrophil/eosinophil granulocytes or monocytes), IL-4 and IL-13 (basophils) were measured by ELISA. RESULTS: Ambroxol inhibited histamine release by more than 50% from human adenoidal mast cells (1000 microM ambroxol) and skin mast cells (100 microM ambroxol) stimulated by Con A and compound 48/80, respectively. Ambroxol (100 microM) strikingly inhibited anti-IgE induced release of both histamine, LTC4, IL-4 and IL-13 from basophils and reduced both histamine and LTB4 release induced by C5a or Zymosan in monocytes. The drug also reduced LTB4 and superoxide anion production in granulocytes stimulated by zymosan or fMLP. In all cell types studied, ambroxol was more efficacious following a short preincubation (5-15 min) of the drug with the cells before stimulation. In contrast, NAC produced no clear effects on any of the different cell types studied, regardless of the preincubation period, the concentration or the stimulus employed. CONCLUSIONS: Unlike NAC, ambroxol is able to not only inhibit acute mediator release from mast cells and leukocytes but also reduce immunomodulatory cytokine generation from basophils and may have beneficial effects in the treatment of allergic respiratory diseases.
Antioxidant function of ambroxol in mononuclear and polymorphonuclear cells in vitro.[Pubmed:9195551]
Lung. 1997;175(4):235-42.
This study quantifies the antioxidant function of ambroxol (2-amino-3,5-dibromo-N-[trans-4-hydroxycyclohexyl]benzylamine) in vitro. Polymorphonuclear cells (PMN) and mononuclear cells were isolated from the blood of healthy volunteers (n = 46) to determine reactive oxygen species (ROS) by luminol-enhanced chemiluminescence. Ambroxol or the controls N-acetylcysteine (NAC), nacystelyn (NAL), glutathione (GSH), superoxide dismutase (SOD), catalase, and the combination of SOD/catalase were incubated for 1 or 2 h with zymosan-activated cells in vitro using concentrations ranging from 10(-6) to 10(-3) mol/liter. Reduction of ROS-mediated luminescence was similar within the cell types. Ambroxol (10(-4) mol/liter) reduced ROS about 75% (1-h incubation) and 98% (2-h incubation), respectively (p < 0.001). SOD and SOD/catalase, but not the H2O2-catalyzing substances (NAC, NAL, GSH, and catalase), reduced cellular ROS. This indicates that inflammatory cells predominantly generate O2-, which can be scavenged by ambroxol. The antioxidant function of ambroxol with increasing incubation time suggests additional cellular antiinflammatory properties of this substance. Our results indicate that good antioxidant function of ambroxol is related mainly to direct scavenger function of reactive oxygen metabolites such as O2-. However, an antioxidative effect of ambroxol may also be associated with the reduction of prooxidative metabolism in inflammatory cells. Concluding from this observation, and because of the well known high affinity of ambroxol for lung tissue, ambroxol may be an alternative in antioxidant augmentation therapy, particularly in pulmonary diseases characterized by an overburden of toxic oxygen metabolites.